Product Information
EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $0.5051 per EA under NDC 00093770456. Its NADAC has been published 288 times since Feb 17, 2021.
FDA first approved this application on Jun 8, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB
Emtricitabine and Tenofovir Disoproxil FumarateStrength
200; 300 mg/1; mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093770456
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATEApproval Type
Generic (ANDA)
FDA Application
ANDA090894FDA Approved
6/8/2017
TE Code
AB
On Market Since
1/20/2021
Pharmacological Classes
Price Statistics
The NADAC for EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB has been published 288 times since Feb 17, 2021, and over the history we have for it it has declined 98.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5051 per EA |
|---|---|
| All-time high | $45.9367 (Apr 14, 2021) |
| All-time low | $0.4258 (May 22, 2024) |
| 52-week high | $0.5904 |
| 52-week low | $0.4508 |
| Median price | $0.5855 |
| Average price | $2.9614 |
| Largest weekly change | -97.1% (Jun 2, 2021) |
| Weeks tracked | 288 |
| Tracking since | Feb 17, 2021 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 11% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB, manufactured by Teva Pharmaceuticals USA Inc., is $0.5051 per EA (NDC 00093770456), effective Aug 19, 2026.
How has the price of EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB changed over time?
Over the history we have for it, the NADAC for EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB has declined 98.9%. It has been tracked across 288 weekly CMS publications since Feb 17, 2021.
What are the highest and lowest recorded NADAC prices for EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB?
Since Feb 17, 2021, the NADAC for EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB has ranged from a low of $0.4258 (May 22, 2024) to a high of $45.9367 (Apr 14, 2021), with a median of $0.5855 per EA.
Are there cheaper alternatives to EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB?
Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB, is $0.4508 per EA — about 11% below EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB.
Who manufactures EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB?
EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB (NDC 00093770456) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.